Literature DB >> 23919362

Observational study of contracts processing at 29 CTSA sites.

James Kiriakis1, Nicholas Gaich, S Claiborne Johnston, Darlene Kitterman, Daniel Rosenblum, Libby Salberg, Adam Rifkind.   

Abstract

We measured contracts final negotiation (FN) and full execution (FE) times using shared definitions in a prospective observational study of management of contracts for clinical trials at 29 CTSA institutions. Median FN and FE times were reached in 39 and 91 days, respectively; mean times for FN and FE were 55 and 103 days, respectively. Individual site medians ranged from 3 to 116 days for FN and 34 to 197 days for FE. The use of master agreements (MAs) and previously negotiated terms (PNTs) was associated with significant reduction of FN times by a mean of 33 days (p < 0) and 22 days (p < 0.001), respectively. PNTs, but not MAs, were associated with significantly reduced FE time (22 days, p < 0.007). Gap analysis revealed a gap of 22 days between contracts negotiation and Institutional Review Board (IRB) review and intervals of 33 days (contracts) and 48 days (IRB review) during which the process steps were being conducted alone, suggesting a potential benefit with parallel processing. These baseline data support a plan to investigate root causes of prolonged study start-up time by examining causes of variation and outliers.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  CTSA Consortium; clinical research management; clinical trials; contracts; public private partnerships; virtual national laboratory

Mesh:

Year:  2013        PMID: 23919362      PMCID: PMC3740442          DOI: 10.1111/cts.12073

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  7 in total

1.  A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors.

Authors:  Kevin A Schulman; Damon M Seils; Justin W Timbie; Jeremy Sugarman; Lauren A Dame; Kevin P Weinfurt; Daniel B Mark; Robert M Califf
Journal:  N Engl J Med       Date:  2002-10-24       Impact factor: 91.245

2.  A virtual national laboratory for reengineering clinical translational science.

Authors:  David M Dilts; Daniel Rosenblum; William M Trochim
Journal:  Sci Transl Med       Date:  2012-01-25       Impact factor: 17.956

3.  Translational and clinical science--time for a new vision.

Authors:  Elias A Zerhouni
Journal:  N Engl J Med       Date:  2005-10-12       Impact factor: 91.245

4.  Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.

Authors:  David M Dilts; Alan B Sandler; Matthew Baker; Steven K Cheng; Stephen L George; Kathleen S Karas; Stephen McGuire; Gourija S Menon; Jason Reusch; Debbie Sawyer; Maren Scoggins; Amy Wu; Kai Zhou; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

5.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

6.  Reengineering translational science: the time is right.

Authors:  Francis S Collins
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

7.  Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.

Authors:  David M Dilts; Alan B Sandler
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

  7 in total
  5 in total

1.  The CTSA Consortium's Catalog of Assets for Translational and Clinical Health Research (CATCHR).

Authors:  Jana Shirey-Rice; Brandy Mapes; Melissa Basford; Anneliese Zufelt; Firas Wehbe; Paul Harris; Michael Alcorn; David Allen; Margaret Arnim; Susan Autry; Michael S Briggs; Andrea Carnegie; Deborah Chavis-Keeling; Carlos De La Pena; Doris Dworschak; Julie Earnest; Terri Grieb; Marilyn Guess; Nathaniel Hafer; Tesheia Johnson; Amanda Kasper; Janice Kopp; Timothy Lockie; Vincetta Lombardo; Leslie McHale; Andrea Minogue; Beth Nunnally; Deanna O'Quinn; Kelly Peck; Kieran Pemberton; Cheryl Perry; Ginny Petrie; Andria Pontello; Rachel Posner; Bushra Rehman; Deborah Roth; Paulette Sacksteder; Samantha Scahill; Lorri Schieri; Rosemary Simpson; Anne Skinner; Kim Toussant; Alicia Turner; Elaine Van der Put; June Wasser; Chris D Webb; Maija Williams; Lori Wiseman; Laurel Yasko; Jill Pulley
Journal:  Clin Transl Sci       Date:  2014-01-23       Impact factor: 4.689

2.  Activating clinical trials: a process improvement approach.

Authors:  Diego A Martinez; Athanasios Tsalatsanis; Ali Yalcin; José L Zayas-Castro; Benjamin Djulbegovic
Journal:  Trials       Date:  2016-02-24       Impact factor: 2.279

Review 3.  Early Vision for the CTSA Program Trial Innovation Network: A Perspective from the National Center for Advancing Translational Sciences.

Authors:  M R Shah; M A Culp; K R Gersing; P L Jones; M E Purucker; T Urv; T M Wilson; P Kaufmann
Journal:  Clin Transl Sci       Date:  2017-04-06       Impact factor: 4.689

4.  A collaborative, academic approach to optimizing the national clinical research infrastructure: The first year of the Trial Innovation Network.

Authors:  Gordon R Bernard; Paul A Harris; Jill M Pulley; Daniel K Benjamin; Jonathan Michael; Daniel E Ford; Daniel F Hanley; Harry P Selker; Consuelo H Wilkins
Journal:  J Clin Transl Sci       Date:  2018-11-27

5.  Drivers of Start-Up Delays in Global Randomized Clinical Trials.

Authors:  Jennifer Lai; Leila Forney; Daniel L Brinton; Kit N Simpson
Journal:  Ther Innov Regul Sci       Date:  2020-09-21       Impact factor: 1.778

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.